MedPath

Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma

Not Applicable
Recruiting
Conditions
Malignant pleural mesothelioma
Registration Number
JPRN-UMIN000034312
Lead Sponsor
Kawasaki Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Initial and resectable malignant pleural mesothelioma

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath